All In Biotech

Free tool

FAERS Monitor: Mirvaso

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204708 or its brand name (Mirvaso, Brimonidine Tartrate). Reports on generic versions are filed under their own applications.

Reports

4,408

Serious

1,945

44% of reports

Hospitalization

758

Death reported

191

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • erythema578
  • drug ineffective297
  • eye pain289
  • flushing285
  • condition aggravated276
  • product use issue256
  • eye irritation227
  • headache196
  • fatigue194
  • skin burning sensation179
  • rosacea174
  • vision blurred173
  • dizziness172
  • ocular hyperaemia172
  • off label use155

Reports by year received

View as table
YearReports
200428
200539
200636
200753
200837
200945
201055
201181
201277
2013101
2014334
2015346
2016234
2017219
2018200
2019196
2020301
2021242
2022259
2023301
2024333
2025381
2026510

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,751 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
rosaceaSignal174185.1159.530,495
eye painSignal28924.622.06,493
eye irritationSignal22718.916.63,823
ocular hyperaemiaSignal17217.415.02,631
erythemaSignal57813.512.56,696
flushingSignal28513.412.03,268
skin burning sensationSignal17911.910.31,787
product use issueSignal2566.55.81,197
vision blurredSignal1736.05.2723
condition aggravatedSignal2764.33.9714
dizziness1721.61.444
headache1961.51.332
fatigue1941.21.06
drug ineffective2971.11.02
off label use1550.80.74

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.